222 related articles for article (PubMed ID: 10891872)
1. Novel compounds in preclinical/early clinical development for the treatment of HIV infections.
De Clercq E
Rev Med Virol; 2000; 10(4):255-77. PubMed ID: 10891872
[TBL] [Abstract][Full Text] [Related]
2. New developments in anti-HIV chemotherapy.
De Clercq E
Curr Med Chem; 2001 Nov; 8(13):1543-72. PubMed ID: 11562282
[TBL] [Abstract][Full Text] [Related]
3. New developments in anti-HIV chemotherapy.
De Clercq E
Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
[TBL] [Abstract][Full Text] [Related]
4. New anti-HIV agents and targets.
De Clercq E
Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
[TBL] [Abstract][Full Text] [Related]
5. New developments in anti-HIV chemotherapy.
De Clercq E
Farmaco; 2001; 56(1-2):3-12. PubMed ID: 11347962
[TBL] [Abstract][Full Text] [Related]
6. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.
Barbaro G; Scozzafava A; Mastrolorenzo A; Supuran CT
Curr Pharm Des; 2005; 11(14):1805-43. PubMed ID: 15892677
[TBL] [Abstract][Full Text] [Related]
7. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection.
De Clercq E
Med Res Rev; 2000 Sep; 20(5):323-49. PubMed ID: 10934347
[TBL] [Abstract][Full Text] [Related]
8. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
[TBL] [Abstract][Full Text] [Related]
9. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.
De Clercq E
Int J Biochem Cell Biol; 2004 Sep; 36(9):1800-22. PubMed ID: 15183346
[TBL] [Abstract][Full Text] [Related]
10. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry.
Daelemans D; Schols D; Witvrouw M; Pannecouque C; Hatse S; van Dooren S; Hamy F; Klimkait T; de Clercq E; VanDamme AM
Mol Pharmacol; 2000 Jan; 57(1):116-24. PubMed ID: 10617686
[TBL] [Abstract][Full Text] [Related]
11. Emerging anti-HIV drugs.
De Clercq E
Expert Opin Emerg Drugs; 2005 May; 10(2):241-73. PubMed ID: 15934866
[TBL] [Abstract][Full Text] [Related]
12. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
13. New advances in HIV entry inhibitors development.
Rusconi S; Scozzafava A; Mastrolorenzo A; Supuran CT
Curr Drug Targets Infect Disord; 2004 Dec; 4(4):339-55. PubMed ID: 15578975
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV drug development--an overview.
Pereira CF; Paridaen JT
Curr Pharm Des; 2004; 10(32):4005-37. PubMed ID: 15579085
[TBL] [Abstract][Full Text] [Related]
15. Virus entry as a target for anti-HIV intervention.
Esté JA
Curr Med Chem; 2003 Sep; 10(17):1617-32. PubMed ID: 12871111
[TBL] [Abstract][Full Text] [Related]
16. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of the effect of temporary removal of HIV drug pressure.
Witvrouw M; Pannecouque C; Desmyter J; De Clercq E; Andries K
Antiviral Res; 2000 Jun; 46(3):215-21. PubMed ID: 10867159
[TBL] [Abstract][Full Text] [Related]
18. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.
Pluymers W; Neamati N; Pannecouque C; Fikkert V; Marchand C; Burke TR; Pommier Y; Schols D; De Clercq E; Debyser Z; Witvrouw M
Mol Pharmacol; 2000 Sep; 58(3):641-8. PubMed ID: 10953059
[TBL] [Abstract][Full Text] [Related]
19. HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
[TBL] [Abstract][Full Text] [Related]
20. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
